Trelagliptin succinate is the world’s first weekly oral DPP 4 inhibitors, used in type 2 diabetes, this product is a weekly dipeptide base peptidase IV (DPP – 4) inhibitors, through selective, sustained suppression DPP – 4, control blood sugar levels. glucose dependence polypeptide (GIP) inactivation, and these two im down an important role in regulating blood sugar. Inhibiting dd-4 can increase blood glucose levels dependent on secretion, which can control blood glucose levels.